Tuesday, November 29, 2005
Treatment of erythematotelangiectactic rosacea with a KTP YAG laser
Case report by Dr. Miller who runs a practice performing KTP YAG treatments for rosacea.
Pubmed Link
Full article PDF on Dr. Miller's website (includes before / after colour photos)
From abstract:
"The flushing and telangiectasias associated with rosacea are notoriously difficult to treat with standard medications. Newer technologies, namely medical lasers and light sources, have made it possible to control and improve erythematotelangietatic signs of rosacea. The potassium-titanyl-phosphate laser in particular is an efficacious and safe tool for treatment of this disease."
Pubmed Link
Full article PDF on Dr. Miller's website (includes before / after colour photos)
From abstract:
"The flushing and telangiectasias associated with rosacea are notoriously difficult to treat with standard medications. Newer technologies, namely medical lasers and light sources, have made it possible to control and improve erythematotelangietatic signs of rosacea. The potassium-titanyl-phosphate laser in particular is an efficacious and safe tool for treatment of this disease."
Saturday, November 19, 2005
Promising Results from Sciton's New Profile
On the R-S Support Group, David Scher has posted some news on his recent treatments using the new Sciton ClearScan laser. David was also one of the first posters on Dr. Soldo - his glowing reviews of him has since encouraged many to seek treatment from Dr. Soldo.
There appears to be numerous advantages to the latest Sciton system including substantially lower cost in treatment and less experience requirements of the practitioner. You can read about these in more detail at Sciton's Website.
Links to David's original comments:
"First Treatment with Sciton's ClearScan"
"Week 1 Progress Post ClearScan TX"
In other forums there has been talk about the Sciton BBL for more effective treatment of the sebaceous glands - in particular this may prove helpful in situations of seborrheic dermatitis or overproductive oil glands.
A word of warning: this is a rather new system. It may be best for most sufferers to wait it out and see the results for a year or so before jumping in. If anything, be cautious.
There appears to be numerous advantages to the latest Sciton system including substantially lower cost in treatment and less experience requirements of the practitioner. You can read about these in more detail at Sciton's Website.
Links to David's original comments:
"First Treatment with Sciton's ClearScan"
"Week 1 Progress Post ClearScan TX"
In other forums there has been talk about the Sciton BBL for more effective treatment of the sebaceous glands - in particular this may prove helpful in situations of seborrheic dermatitis or overproductive oil glands.
A word of warning: this is a rather new system. It may be best for most sufferers to wait it out and see the results for a year or so before jumping in. If anything, be cautious.
Thursday, November 17, 2005
Rosacea and dobesilate
Looks interesting, will try and write more later when I have more time:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&db=PubMed&cmd=Retrieve&list_uids=16287608&dopt=Abstract
Eur J Med Res. 2005 Oct 18;10(10):454-456.
Therapeutic Response of Rosacea to Dobesilate.
Cuevas P, Arrazola JA.
Servicio de Histologia, Departamento de Investigacion, Hospital Ramon y Cajal, Ctra. de Colmenar, km. 9.100, E-28034-Madrid - Spain.
Despite an incomplete understanding of the pathogenesis of rosacea, therapeutic modalities continue to expand. The principal subtype of rosacea includes erythematotelangiestatic rosacea, which is characterized by uncontrolled angiogenesis. Angiogenic growth factors such as fibroblast growth factors (FGF) and vascular endothelial growth factor (VEGF) are currently targets of intense effort to inhibit deregulated blood vessel formation in diseases such as cancer. Here we report a 33-years-old woman with erythematotelangestatic rosacea who responds to a daily treatment of topically applied dobesilate, an inhibitor of FGF, with an improvement in erythema and telangectasia after two weeks. Thus, dobesilate might be useful in the treatment of rosacea and other diseases that depend on pathologic angiogenesis.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&db=PubMed&cmd=Retrieve&list_uids=16287608&dopt=Abstract
Eur J Med Res. 2005 Oct 18;10(10):454-456.
Therapeutic Response of Rosacea to Dobesilate.
Cuevas P, Arrazola JA.
Servicio de Histologia, Departamento de Investigacion, Hospital Ramon y Cajal, Ctra. de Colmenar, km. 9.100, E-28034-Madrid - Spain.
Despite an incomplete understanding of the pathogenesis of rosacea, therapeutic modalities continue to expand. The principal subtype of rosacea includes erythematotelangiestatic rosacea, which is characterized by uncontrolled angiogenesis. Angiogenic growth factors such as fibroblast growth factors (FGF) and vascular endothelial growth factor (VEGF) are currently targets of intense effort to inhibit deregulated blood vessel formation in diseases such as cancer. Here we report a 33-years-old woman with erythematotelangestatic rosacea who responds to a daily treatment of topically applied dobesilate, an inhibitor of FGF, with an improvement in erythema and telangectasia after two weeks. Thus, dobesilate might be useful in the treatment of rosacea and other diseases that depend on pathologic angiogenesis.
